Key result
Intravenous nebivolol cuts reperfusion-induced VT ~61% vs vehicle in rats.
Why the study?
The antiarrhythmic effects of nebivolol, a cardioselective beta 1-adrenoceptor blocker with nitric oxide release properties, were investigated in various experimental in vivo models.
Does nebivolol reduce arrhythmias in experimental animal models?
Population
Experimental in vivo models including rats and guinea pigs with induced arrhythmias and cardiotoxicity
Comparison
Nebivolol 1.25 mg/kg i.v. (or 0.16-2.5 mg/kg i.v. dose-dependent) vs solvent
Design
Preclinical experimental study
Authors
Loading...
Does not support clinical use; hypothesis-generating for nebivolol in reperfusion arrhythmia models.
Does nebivolol reduce arrhythmias in experimental animal models?
Absolute Event Rate: 33% vs 85%
p-value: p=< 0.05
Nebivolol demonstrates significant antiarrhythmic effects across multiple in vivo experimental models of arrhythmia.
Lu et al. (1994) studied Experimental arrhythmias. Nebivolol vs. Solvent was evaluated on Incidence of ventricular tachycardia (VT) in reperfusion-induced arrhythmias (p=< 0.05). Nebivolol 1.25 mg/kg i.v. significantly reduced the incidence of ventricular tachycardia from 85% to 33% (p < 0.05) in reperfusion-induced arrhythmias in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: